NASDAQ:CLSN - Celsion Stock Price, Price Target & More

Get Started

$2.49 -0.04 (-1.58 %)

(As of 05/25/2018 04:00 PM ET)

Previous Close$2.49

Today's Range$2.46 - $2.5015

52-Week Range$1.24 - $6.06

Volume63,651 shs

Average Volume263,908 shs

Market Capitalization$45.01 million

P/E Ratio-1.04

Dividend YieldN/A

Beta1.68

About Celsion (NASDAQ:CLSN)

Celsion Corporation, a development stage oncology drug company, focuses on the development and commercialization of directed chemotherapy, DNA-mediated immunotherapy, and RNA based therapy products for the treatment of cancer. The company's lead product includes ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trials for primary liver cancer; and under Phase II clinical trials to treat recurrent chest wall breast cancer. It is also developing GEN-1, a DNA-based immunotherapeutic product for the localized treatment of ovarian and brain cancers. Celsion Corporation was founded in 1982 and is headquartered in Lawrenceville, New Jersey.

Receive CLSN News and Ratings via Email

Sign-up to receive the latest news and ratings for CLSN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

SymbolNASDAQ:CLSN

CUSIPN/A

Webwww.celsion.com

Phone609-896-9100

Debt

Debt-to-Equity RatioN/A

Current Ratio3.70

Quick Ratio3.70

Price-To-Earnings

Trailing P/E Ratio-1.04

Forward P/E Ratio-2.24

P/E GrowthN/A

Sales & Book Value

Annual Sales$500,000.00

Price / Sales87.90

Cash FlowN/A

Price / CashN/A

Book Value$1.34 per share

Price / Book1.86

Profitability

EPS (Most Recent Fiscal Year)($2.39)

Net Income$-20,400,000.00

Net Margins-3,897.86%

Return on Equity-112.83%

Return on Assets-47.72%

Miscellaneous

Employees21

Outstanding Shares17,650,000

Celsion (NASDAQ:CLSN) Frequently Asked Questions

What is Celsion's stock symbol?

Celsion trades on the NASDAQ under the ticker symbol "CLSN."

When did Celsion's stock split? How did Celsion's stock split work?

Shares of Celsion reverse split on the morning of Tuesday, May 30th 2017. The 1-14 reverse split was announced on Friday, May 26th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, May 26th 2017. An investor that had 100 shares of Celsion stock prior to the reverse split would have 7 shares after the split.

How were Celsion's earnings last quarter?

Celsion Co. (NASDAQ:CLSN) posted its quarterly earnings results on Friday, May, 11th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.30) by $0.05. The biotechnology company had revenue of $0.13 million for the quarter, compared to the consensus estimate of $0.13 million. Celsion had a negative net margin of 3,897.86% and a negative return on equity of 112.83%. View Celsion's Earnings History.

When is Celsion's next earnings date?

Celsion is scheduled to release their next quarterly earnings announcement on Monday, August, 13th 2018. View Earnings Estimates for Celsion.

What price target have analysts set for CLSN?

2 analysts have issued twelve-month target prices for Celsion's stock. Their predictions range from $7.00 to $9.00. On average, they expect Celsion's stock price to reach $8.00 in the next twelve months. View Analyst Ratings for Celsion.

Who are some of Celsion's key competitors?

Some companies that are related to Celsion include Sol Gel Technologies (SLGL), Nature's Sunshine Products Common Stock (NATR), Sierra Oncology (SRRA), Aldeyra Therapeutics (ALDX), Zafgen (ZFGN), Fortress Biotech (FBIO), Nabriva Therapeutics (NBRV), BioXcel Therapeutics (BTAI), Newron Pharmaceuticals (NWPHF), AcelRx Pharmaceuticals (ACRX), Spero Therapeutics (SPRO), Eleven Biotherapeutics (EBIO), Affimed (AFMD), Intec Pharma (NTEC) and Galectin Therapeutics Inc. Common Stock (GALT).

Who are Celsion's key executives?

Celsion's management team includes the folowing people:

Mr. Michael H. Tardugno, Exec. Chairman, Pres & CEO (Age 67)
Mr. Jeffrey W. Church, CFO, Sr. VP of Corp. Strategy & IR and Corp. Sec. (Age 61)
Dr. Khursheed Anwer, Exec. VP & Chief Scientific Officer (Age 58)
Dr. Nicholas Borys, Sr. VP & Chief Medical Officer (Age 59)
Mr. Timothy J. Tumminello CPA, Chief Accounting Officer and Controller (Age 60)

Has Celsion been receiving favorable news coverage?

Media stories about CLSN stock have trended somewhat positive this week, according to Accern Sentiment Analysis. The research firm identifies positive and negative news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Celsion earned a coverage optimism score of 0.12 on Accern's scale. They also gave headlines about the biotechnology company an impact score of 46.66 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next few days.

Who are Celsion's major shareholders?

Celsion's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Sabby Management LLC (2.08%). Company insiders that own Celsion stock include Alberto R Martinez Jr, Frederick J Fritz and Michael H Tardugno. View Institutional Ownership Trends for Celsion.

Which institutional investors are buying Celsion stock?

CLSN stock was purchased by a variety of institutional investors in the last quarter, including Sabby Management LLC. Company insiders that have bought Celsion stock in the last two years include Alberto R Martinez Jr, Frederick J Fritz and Michael H Tardugno. View Insider Buying and Selling for Celsion.

How do I buy shares of Celsion?

Shares of CLSN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Celsion's stock price today?

One share of CLSN stock can currently be purchased for approximately $2.49.

How big of a company is Celsion?

Celsion has a market capitalization of $45.01 million and generates $500,000.00 in revenue each year. The biotechnology company earns $-20,400,000.00 in net income (profit) each year or ($2.39) on an earnings per share basis. Celsion employs 21 workers across the globe.

How can I contact Celsion?

Celsion's mailing address is 997 LENOX DRIVE SUITE 100, LAWRENCEVILLE NJ, 08648. The biotechnology company can be reached via phone at 609-896-9100 or via email at [email protected]

MarketBeat Community Rating for Celsion (CLSN)

Community Ranking:		3.1 out of 5 ( )
Outperform Votes:		267 (Vote Outperform)
Underperform Votes:		166 (Vote Underperform)
Total Votes:		433

MarketBeat's community ratings are surveys of what our community members think about Celsion and other stocks. Vote "Outperform" if you believe CLSN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CLSN will underperform the S&P 500 over the long term. You may vote once every thirty days.

Celsion (NASDAQ:CLSN) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

2 Wall Street analysts have issued ratings and price targets for Celsion in the last 12 months. Their average twelve-month price target is $8.00, suggesting that the stock has a possible upside of 221.29%. The high price target for CLSN is $9.00 and the low price target for CLSN is $7.00. There are currently 2 buy ratings for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	Buy
Consensus Rating Score:	3.00	3.00	3.00	3.00
Ratings Breakdown:	0 Sell Rating(s) 0 Hold Rating(s) 2 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 2 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 4 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 4 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$8.00	$8.00	$14.50	$14.50
Price Target Upside:	221.29% upside	273.83% upside	577.57% upside	577.57% upside

Celsion (NASDAQ:CLSN) Consensus Price Target History

Price Target History for Celsion (NASDAQ:CLSN)

Celsion (NASDAQ:CLSN) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
11/21/2017	Oppenheimer	Initiated Coverage	Outperform	$9.00	N/A
10/4/2017	Maxim Group	Upgrade	Hold ➝ Buy	$7.00	High
4/10/2017	Rodman & Renshaw	Reiterated Rating	Buy	$21.00	High
4/10/2017	HC Wainwright	Reiterated Rating	Buy	$21.00	High

(Data available from 5/25/2016 forward)

Celsion (NASDAQ:CLSN) Earnings History and Estimates Chart

Earnings by Quarter for Celsion (NASDAQ:CLSN)

Celsion (NASDAQ:CLSN) Earnings Estimates

2018 EPS Consensus Estimate: ($1.34)

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	1	($0.37)	($0.37)	($0.37)
Q2 2018	2	($0.39)	($0.27)	($0.33)
Q3 2018	2	($0.38)	($0.26)	($0.32)
Q4 2018	2	($0.33)	($0.30)	($0.32)

Celsion (NASDAQ CLSN) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
8/13/2018
5/11/2018	Q1 2018	($0.30)	($0.25)	$0.13 million	$0.13 million	View	N/A
11/14/2017	Q3 2017	($0.56)	($0.39)	$0.13 million	$0.13 million	View	N/A
8/14/2017	Q2 2017	($1.10)	($0.79)	$0.13 million	$0.13 million	View	N/A
5/18/2017	Q1 2017	($1.3020)	($1.6380)	$0.13 million	$0.13 million	View	N/A
3/16/2017	Q4 2016	($2.24)	($1.96)	$0.13 million	$0.13 million	View	N/A
11/10/2016	Q3 2016	($2.66)	($3.22)	$0.13 million	$0.13 million	View	N/A
8/15/2016	Q2	($2.94)	($2.66)	$0.13 million	$0.13 million	View	Listen
5/16/2016	Q116	($2.94)	($3.36)	$0.13 million	$0.13 million	View	Listen
3/30/2016	Q415	($3.36)	($3.36)	$0.16 million	$0.13 million	View	Listen
11/5/2015	Q315	($3.64)	($2.80)	$0.14 million	$0.13 million	View	N/A
8/10/2015	Q215	($4.34)	($3.78)	$0.16 million	$0.13 million	View	Listen
5/12/2015	Q1	($4.62)	($4.76)	$0.13 million	$0.13 million	View	N/A
3/12/2015	Q4 2014	($5.04)	($4.48)	$0.13 million	$0.13 million	View	N/A
11/11/2014	Q3 2014	($4.20)	($4.90)	$0.16 million	$0.13 million	View	N/A
8/7/2014	Q214	($3.92)	($4.48)	$0.13 million	$0.13 million	View	N/A
5/8/2014	Q1 2014	($2.80)	($4.62)	$0.13 million	$0.13 million	View	N/A
3/13/2014		($3.92)	($2.66)	$0.13 million	$0.13 million	View	N/A
11/12/2013	Q3	($3.15)	($4.20)		$0.1250 million	View	Listen
8/8/2013	Q2 2013	($0.98)	$0.14		$0.1250 million	View	N/A
5/9/2013	Q1 2013	($2.24)	($1.68)	$0.38 million	$0.13 million	View	N/A
3/18/2013	Q4 2012	($10.72)	($13.24)			View	N/A
11/12/2012	Q312	($2.38)	($2.52)			View	N/A
8/14/2012	Q2 2012	($11.98)	($11.60)			View	N/A
5/15/2012	Q1 2012	($13.24)	($11.72)			View	N/A
3/15/2012	Q4 2011	($13.87)	($11.35)			View	N/A
11/10/2011	Q3 2011	($16.39)	($16.01)			View	N/A
8/9/2011	Q2 2011		($24.46)			View	N/A
5/12/2011	Q1 2011		($18.41)			View	N/A
3/25/2011	Q4 2010		($26.47)			View	N/A
11/15/2010	Q3 2010	($23.32)	($24.08)			View	N/A
8/3/2010	Q2 2010	($23.95)	($23.01)			View	N/A
5/4/2010	Q1 2010	($20.17)	($23.64)			View	N/A
2/17/2010	Q4 2009	($22.69)	($11.85)			View	N/A
11/10/2009	Q3 2009		($29.37)			View	N/A
8/5/2009	Q2 2009		($28.36)			View	N/A
5/12/2009	Q1 2009		($22.38)			View	N/A
3/3/2009	Q4 2008		($5.80)			View	N/A
11/13/2008	Q3 2008		($26.98)			View	N/A
8/18/2008	Q2 2008		($15.06)			View	N/A
5/8/2008	Q1 2008		($25.34)			View	N/A
2/21/2008	Q4 2007		($15.00)			View	N/A

(Earnings results data provided by Zacks Investment Research)

Celsion (NASDAQ:CLSN) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

Celsion (NASDAQ CLSN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 2.40%
Institutional Ownership Percentage: 6.47%

Insider Trading History for Celsion (NASDAQ:CLSN)

Institutional Ownership by Quarter for Celsion (NASDAQ:CLSN)

Celsion (NASDAQ CLSN) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/9/2018	Michael H Tardugno	CEO	Buy	2,500	$2.30	$5,750.00	20,200
3/5/2018	Michael H Tardugno	CEO	Buy	7,500	$2.38	$17,850.00	17,700
2/22/2018	Alberto R Martinez Jr	Director	Buy	7,143	$2.17	$15,500.31	20,000
2/20/2018	Frederick J Fritz	Director	Buy	6,000	$2.17	$13,020.00	12,841
7/7/2017	Frederick J Fritz	Director	Buy	13,000	$1.89	$24,570.00	9,841
2/21/2017	Alberto R Martinez Jr	Director	Buy	35,000	$0.23	$8,050.00	180,081
2/15/2017	Alberto R Martinez Jr	Director	Buy	45,000	$0.22	$9,900.00	145,081
11/14/2016	Alberto R Martinez Jr	Director	Buy	10,000	$0.86	$8,600.00	100,081
11/11/2016	Alberto R Martinez Jr	Director	Buy	10,000	$0.91	$9,100.00	90,081
10/7/2016	Michael H Tardugno	Chairman	Buy	10,000	$1.14	$11,400.00	143,021
8/16/2016	Alberto R Martinez Jr	Director	Buy	5,000	$1.25	$6,250.00	80,081
6/17/2016	Alberto R Martinez Jr	Director	Buy	5,000	$1.35	$6,750.00	75,081
6/16/2016	Michael H Tardugno	CEO	Buy	7,500	$1.35	$10,125.00	128,021
2/19/2016	Michael H Tardugno	CEO	Buy	3,000	$1.27	$3,810.00	120,521
2/17/2016	Michael H Tardugno	CEO	Buy	2,000	$1.27	$2,540.00	117,521
2/16/2016	Alberto R Martinez Jr	Director	Buy	5,000	$1.16	$5,800.00	70,081
2/16/2016	Michael H Tardugno	CEO	Buy	4,500	$1.20	$5,400.00	115,521
2/12/2016	Michael H Tardugno	CEO	Buy	6,500	$1.13	$7,345.00	111,021
12/3/2015	Egwu, Inc. Fka Egen, Inc.	Major Shareholder	Sell	5,556	$2.08	$11,556.48	2,421,867
11/30/2015	Egwu, Inc. Fka Egen, Inc.	Major Shareholder	Sell	20,000	$2.15	$43,000.00	2,442,423
9/8/2015	Egwu, Inc. Fka Egen, Inc.	Major Shareholder	Sell	10,000	$2.11	$21,100.00	2,462,423
8/17/2015	Egwu, Inc. Fka Egen, Inc.	Major Shareholder	Sell	10,000	$2.19	$21,900.00	2,472,423
8/13/2015	Egwu, Inc. Fka Egen, Inc.	Major Shareholder	Sell	20,000	$2.23	$44,600.00
5/13/2015	Alberto R Martinez Jr	Director	Buy	5,000	$2.50	$12,500.00
12/18/2014	Frederick J Fritz	Director	Buy	4,000	$2.34	$9,360.00
11/13/2014	Robert W Hooper	Director	Buy	4,000	$2.50	$10,000.00
8/15/2014	Alberto R Martinez Jr	Director	Buy	5,000	$3.12	$15,600.00
8/15/2014	Michael H Tardugno	CEO	Buy	4,000	$3.12	$12,480.00
8/14/2014	Frederick J Fritz	Director	Buy	4,000	$3.20	$12,800.00
6/26/2014	Alberto R Martinez Jr	Director	Buy	5,000	$3.36	$16,800.00
6/11/2014	Michael H Tardugno	CEO	Buy	5,000	$3.20	$16,000.00
3/14/2014	Frederick Fritz	Director	Buy	2,500	$3.86	$9,650.00	21,331
3/14/2014	Michael Tardugno	CEO	Buy	4,000	$3.84	$15,360.00	57,521
11/19/2013	Michael Tardugno	CEO	Buy	2,800	$3.59	$10,052.00	53,521
11/15/2013	Frederick Fritz	Director	Buy	3,000	$3.80	$11,400.00	14,331
8/16/2013	Frederick Fritz	Director	Buy	10,000	$1.09	$10,900.00	51,000
8/16/2013	Michael Tardugno	CEO	Buy	5,000	$1.08	$5,400.00	228,285
6/12/2013	Michael H Tardugno	CEO	Buy	10,000	$1.35	$13,500.00
5/21/2013	Alberto R Martinez Jr	Director	Buy	5,000	$0.93	$4,650.00
5/13/2013	Alberto R Martinez Jr	Director	Buy	5,000	$0.96	$4,800.00
5/10/2013	Alberto R Martinez Jr	Director	Buy	5,000	$0.92	$4,600.00
3/20/2013	Alberto R Martinez Jr	Director	Buy	3,750	$1.06	$3,975.00
12/10/2012	Max Link	Director	Buy	14,000	$7.60	$106,400.00
11/15/2012	Robert W Hooper	Director	Buy	11,600	$5.20	$60,320.00
9/14/2012	Michael H Tardugno	CEO	Buy	5,000	$5.03	$25,150.00
9/10/2012	Robert W Hooper	Director	Buy	10,000	$4.95	$49,500.00
8/29/2012	Robert W Hooper	Director	Buy	2,500	$4.65	$11,625.00

(Data available from 1/1/2013 forward)

Celsion (NASDAQ CLSN) News Headlines

Source:

Date	Headline
	Zacks Investment Research Upgrades Celsion (CLSN) to "Buy" www.americanbankingnews.com - May 17 at 8:08 PM
	Oppenheimer Comments on Celsion Co.'s Q2 2018 Earnings (CLSN) www.americanbankingnews.com - May 17 at 6:34 AM
	Celsion's (CLSN) CEO Michael Tardugno on Q1 2018 Results - Earnings Call Transcript seekingalpha.com - May 12 at 10:24 AM
	Celsion net loss improves in Q1; shares ahead 14% premarket seekingalpha.com - May 12 at 10:24 AM
	Edited Transcript of CLSN earnings conference call or presentation 11-May-18 3:00pm GMT finance.yahoo.com - May 12 at 10:24 AM
	Celsion (CLSN) Announces Earnings Results, Beats Estimates By $0.05 EPS www.americanbankingnews.com - May 11 at 4:36 PM
	Form 10-Q Celsion CORP For: Mar 31 www.streetinsider.com - May 11 at 11:07 AM
	Celsion Corporation Reports First Quarter 2018 Financial Results and Provides Business Update finance.yahoo.com - May 11 at 11:07 AM
	Celsion Corporation to Present at the RHK Capital 2018 Disruptive Growth and Healthcare Conference finance.yahoo.com - May 8 at 9:50 AM
	Celsion (CLSN) to Release Earnings on Friday www.americanbankingnews.com - May 7 at 8:46 AM
	Celsion Corporation to Hold First Quarter 2018 Financial Results Conference Call on Friday, May 11, 2018 finance.yahoo.com - May 4 at 9:45 AM
	Celsion (CLSN) Upgraded to "Hold" at ValuEngine www.americanbankingnews.com - May 3 at 10:19 PM
	International Liver Congress™ 2018 Symposium Highlights Celsion's ThermoDox® in Treatment of Primary Liver Cancer globenewswire.com - April 12 at 10:53 AM
	International Liver Congress™ 2018 Symposium Highlights Celsion’s ThermoDox® in Treatment of Primary Liver Cancer finance.yahoo.com - April 12 at 10:53 AM
	Form 4 Celsion CORP For: Apr 09 Filed by: Tardugno Michael H www.streetinsider.com - April 9 at 4:07 PM
	Celsion (CLSN) Says DMC Completes Planned Safety and Data Review of its Phase III OPTIMA Study of ThermoDox in ... www.streetinsider.com - April 9 at 4:07 PM
	Data Monitoring Committee (DMC) Completes Planned Safety and Data Review of Celsion's Phase III OPTIMA Study of ... globenewswire.com - April 9 at 10:23 AM
	Data Monitoring Committee (DMC) Completes Planned Safety and Data Review of Celsion’s Phase III OPTIMA Study of ThermoDox® in Primary Liver Cancer finance.yahoo.com - April 9 at 10:23 AM
	Celsion (CLSN) Cut to "Sell" at Zacks Investment Research www.americanbankingnews.com - April 3 at 9:54 PM
	Celsion (CLSN) Downgraded to Sell at ValuEngine www.americanbankingnews.com - March 28 at 10:22 PM
	Edited Transcript of CLSN earnings conference call or presentation 27-Mar-18 3:00pm GMT finance.yahoo.com - March 28 at 10:01 AM
	Celsion Corporation Reports Fourth Quarter and Full-Year 2017 Financial Results finance.yahoo.com - March 27 at 10:11 AM
	Celsion Co. (CLSN) Receives Consensus Recommendation of "Buy" from Analysts www.americanbankingnews.com - March 26 at 8:26 AM
	Celsion (CLSN) Downgraded by ValuEngine to Strong Sell www.americanbankingnews.com - March 25 at 7:32 PM
	Celsion (CLSN) Lifted to Hold at ValuEngine www.americanbankingnews.com - March 23 at 11:20 PM
	Celsion (CLSN) Set to Announce Quarterly Earnings on Tuesday www.americanbankingnews.com - March 23 at 8:20 PM
	$130,000.00 in Sales Expected for Celsion Co. (CLSN) This Quarter www.americanbankingnews.com - March 21 at 8:49 AM
	Celsion Corporation to Hold Year-End 2017 Financial Results Conference Call on Tuesday, March 27, 2018 finance.yahoo.com - March 20 at 9:51 AM
	Celsion (CLSN) Rating Increased to Sell at ValuEngine www.americanbankingnews.com - March 19 at 11:48 PM
	Critical Comparison: Celsion (CLSN) versus Edge Therapeutics (EDGE) www.americanbankingnews.com - March 17 at 3:06 AM
	Celsion (CLSN) Downgraded by ValuEngine www.americanbankingnews.com - March 16 at 12:48 AM
	Celsion Corporation to Present at Upcoming Investor Conferences finance.yahoo.com - March 12 at 4:02 PM
	Celsion Co. (CLSN) CEO Michael H. Tardugno Acquires 7,500 Shares www.americanbankingnews.com - March 5 at 12:38 PM
	Celsion Announces Ovarian Cancer Expert Presentation at Oppenheimer & Co. Investor Event finance.yahoo.com - March 5 at 10:59 AM
	Zacks: Analysts Anticipate Celsion Co. (CLSN) Will Announce Quarterly Sales of $130,000.00 www.americanbankingnews.com - March 4 at 5:46 AM
	-$0.31 EPS Expected for Celsion Co. (CLSN) This Quarter www.americanbankingnews.com - March 2 at 12:08 PM
	Celsion Co. (CLSN) Given Consensus Rating of "Buy" by Analysts www.americanbankingnews.com - March 1 at 12:10 PM
	Celsion Co. (CLSN) Director Purchases $15,500.31 in Stock www.americanbankingnews.com - February 22 at 3:26 PM
	Frederick J. Fritz Acquires 6,000 Shares of Celsion Co. (CLSN) Stock www.americanbankingnews.com - February 21 at 12:31 PM
	Analysts Expect Celsion Co. (CLSN) Will Announce Quarterly Sales of $130,000.00 www.americanbankingnews.com - February 15 at 3:36 AM
	Zacks: Brokerages Expect Celsion Co. (CLSN) to Announce -$0.31 EPS www.americanbankingnews.com - February 13 at 3:12 PM
	Celsion Announces ThermoDox® HEAT Study Presentation at Korean Liver Cancer Association's 12th Annual ... - GlobeNewswire (press release) globenewswire.com - February 13 at 6:01 AM
	Celsion Announces ThermoDox® HEAT Study Presentation at Korean Liver Cancer Association’s 12th Annual Scientific Meeting finance.yahoo.com - February 12 at 3:21 PM
	Celsion Co. (CLSN) Receives Average Rating of "Buy" from Brokerages www.americanbankingnews.com - February 4 at 8:02 AM
	Celsion Co. (CLSN) Expected to Announce Quarterly Sales of $130,000.00 www.americanbankingnews.com - January 29 at 3:46 AM
	Celsion Corporation Provides Corporate Update and 2018 Outlook finance.yahoo.com - January 18 at 10:38 AM
	Celsion (CLSN) Downgraded to Hold at Zacks Investment Research www.americanbankingnews.com - January 11 at 7:48 PM
	Zacks: Analysts Anticipate Celsion Co. (CLSN) to Announce -$0.31 Earnings Per Share www.americanbankingnews.com - January 10 at 5:28 PM
	Celsion Co. (CLSN) Given Consensus Recommendation of "Buy" by Brokerages www.americanbankingnews.com - January 10 at 8:18 AM
	Celsion's Phase I/II Cancer Study Initiation Gets FDA Nod - Nasdaq www.nasdaq.com - January 5 at 4:54 PM

Celsion (NASDAQ:CLSN) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Celsion (NASDAQ:CLSN) Income Statement, Balance Sheet and Cash Flow Statement

Celsion (NASDAQ CLSN) Stock Chart for Friday, May, 25, 2018

Loading chart…

This page was last updated on 5/25/2018 by MarketBeat.com Staff